Cognitive functions in methamphetamine induced psychosis compared to schizophrenia and normal subjects
Objective: The purpose of this research was to study the cognitive functions in patients with methamphetamine-induced psychosis (MIP) in comparison with schizophrenia patients and normal subjects.
Method: This was a cross-sectional study, 30 patients with MIP, 30 patients with schizophrenia and 30 normal individuals were selected via convenient sampling and were matched on age, sex and education. Wisconsin Cards Sorting, Stroop, Visual Search and Attention and Wechsler Memory Tests were used to assess the subjects.
Results: The study showed that patients with MIP and schizophrenia have more deficits in executive functions, selective attention, sustained attention and memory than normal subjects. There were no significant differences in cognitive functions between patients with MIP and schizophrenia except for visual search and attention that showed more impairment in patients with schizophrenia.
Conclusion: Although, cognitive dysfunctions of patients with MIP are mostly similar to patients with schizophrenia, some differences seem to exist, especially in those functions that are not primarily dependent on frontal lobe.
Shariat SV, Elahi A. Symptoms and course of psychosis after methamphetamine abuse: One year follow up of a case. Prim Care Companion J Clin Psychiatry 2010; 12:e1-e2.
Fasihpour B, Molavi S, Shariat SV. Clinical features of inpatients with methamphetamine induced psychosis. J Ment Health 2013; 22: 341-349.
Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 2007; 17: 275-297.
Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, et al. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 2004 30: 6028-6036.
Chou YH, Huang WS, Su TP, Lu RB, Wan FJ, Fu YK. Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: A SPECT study. Eur Neuropsychopharmacol 2007; 17: 46-52.
Kalechstein AD, Newton TF, Green M. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci 2003; 15: 215-220.
Rendell PG, Mazur M, Henry JD. Prospective memory impairment in former users of methamphetamine. Psychopharmacology (Berl) 2009; 203: 609-616.
Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 2005; 13: 141-154.
9.Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004; 15: 29-39.
Rund BR. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr Bull 1998; 24: 425-435.
Heinrichs RW, Zakzanis KK. Neurocognitive Deficit in Schizophrenia: A Quantitative Review of the Evidence. Neuropsychology 1998; 12: 426-445.
Harvey P, Bowie C, Friedman J. Cognition in schizophrenia. Curr Psychiatry Rep 2001; 3: 423-428.
Jacobs E, Fujii D, Schiffman J, Bello I. An exploratory analysis of neurocognition in methamphetamine-induced psychotic disorder and paranoid schizophrenia. Cogn Behav Neurol 2008; 21: 98–103.
Berg EA. A simple objective technique for measuring flexibility in thinking. J Gen Psychol 1948; 39: 15-22.
Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935; 28: 643-662.
Trenerry MR, Crosson B, DeBoe J, Leber WR. Visual Search and Attention Test. Odessa, Florida: Psychological Assessment Resources, Inc.; 1990.
Filoteo JV, Williams BJ, Rilling LM, Roberts JV. Performance of Parkinson's disease patients on the Visual Search and Attention Test: impairment in single-feature but not dual-feature visual search. Arch Clin Neuropsychol 1997; 12: 621-634.
Wechsler D. A Standardized Memory Scale for Clinical Use. J Psychol 1945 2012/06/16; 19: 87-95.
Quinton MS, Yamamoto BK. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J 2006; 8: 337-347.
Salo R, Nordahl TE, Galloway GP, Moore CD, Waters C, Leamon MH. Drug abstinence and cognitive control in methamphetamine-dependent individuals. J Subst Abuse Treat 2009; 37: 292-197.
Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, Braff DL, et al. Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. Neuropsychopharmacology 2002; 26:53–63.
Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 2001; 158: 1206-1214.
Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158: 377-382.
McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with (11C) WIN-35,428. J Neurosci 1998; 18: 8417-8422.
Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 2003; 160: 1699-1701.
Ernst T, Chang L, Leonido-Yee M, Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology 2000; 28:1344-1349.
Chang L, Ernst T, Speck O, Patel H, DeSilva M, Leonido-Yee M, et al. Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res 2002; 114: 65-79.
Eisch AJ, Marshall JF. Methamphetamine neurotoxicity: dissociation of striatal dopamine terminal damage from parietal cortical cell body injury. Synapse 1998; 30: 433-45.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.